Literature DB >> 8944336

Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy.

R Demicheli1, A Abbattista, R Miceli, P Valagussa, G Bonadonna.   

Abstract

PURPOSE: To gather information on metastatic growth from the time-distribution of first treatment failure in breast cancer patients undergoing mastectomy alone.
METHODS: The risk of recurrence at a given time after surgery was studied utilizing the cause-specific hazard function. Recurrence was categorized as first treatment failure at any site, local-regional recurrence, distant metastases, and contralateral tumor. The risk distribution was assessed relative to tumor size, axillary lymph node involvement, and menopausal status.
RESULTS: A total of 1173 patients treated between 1964 and 1980 with mastectomy alone and no adjuvant therapy were studied. The hazard function for first failure presented an early peak at about 18 months after surgery, a second peak at about 60 months and then a tapered plateau-like tail extending up to 15 years. A similar risk pattern was detectable for both local recurrence and distant metastases, while the curve of contralateral breast tumors showed a near flat plateau. The risk of early local-regional and distant recurrences was much lower for tumors less than 2 cm in diameter than for larger tumors; the risk of late recurrence was similar for small and large primaries. Node-positive patients showed peaks four to five times higher than node-negative patients. Sub-dividing node-positive patients into 1-3 and > 3 node-positive subsets did not substantially change the general picture of tumor recurrence. The hazard functions for premenopausal and postmenopausal patients were virtually superimposable.
CONCLUSIONS: The multipeak hazard curve suggests that the process resulting in overt clinical metastases may have discrete features. Primary tumor size could affect in different ways early and late metastases, while axillary node status should be related to the risk level, not to the risk pattern, and menopausal status does not seem to significantly affect the hazard distribution. Moreover, contralateral breast tumors, occurring at constant risk throughout the time, should be considered as second primary cancers. These findings could be reasonably explained by a tumor dormancy hypothesis, which assumes that micrometastases may be in different biological steady states, most of which do not imply tumor growth. Tumor or microenvironment changes could induce metastatic growth after given mean transition times from surgery and originate a discrete pattern of the hazard function.

Entities:  

Mesh:

Year:  1996        PMID: 8944336     DOI: 10.1007/bf01807163

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  31 in total

Review 1.  The biology of renal cancer metastasis.

Authors:  I J Fidler
Journal:  Semin Urol       Date:  1992-02

2.  Salvage treatments in relapsing resectable breast cancer.

Authors:  P Valagussa; C Brambilla; M Zambetti; G Bonadonna
Journal:  Recent Results Cancer Res       Date:  1989

3.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

Review 4.  Implications of kinetic heterogeneity in clinical oncology.

Authors:  L Norton
Journal:  Semin Oncol       Date:  1985-09       Impact factor: 4.929

5.  Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up.

Authors:  P P Rosen; S Groshen; D W Kinne; L Norton
Journal:  J Clin Oncol       Date:  1993-11       Impact factor: 44.544

6.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

7.  Bilateral primary breast cancer: a prospective study of disease incidence.

Authors:  M A Chaudary; R R Millis; E O Hoskins; M Halder; R D Bulbrook; J Cuzick; J L Hayward
Journal:  Br J Surg       Date:  1984-09       Impact factor: 6.939

8.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update.

Authors:  B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

9.  Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients.

Authors:  P Valagussa; G Bonadonna; U Veronesi
Journal:  Cancer       Date:  1978-03       Impact factor: 6.860

10.  Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice.

Authors:  S M Shafie; F H Grantham
Journal:  J Natl Cancer Inst       Date:  1981-07       Impact factor: 13.506

View more
  70 in total

Review 1.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 2.  Rethinking the metastatic cascade as a therapeutic target.

Authors:  Lida A Mina; George W Sledge
Journal:  Nat Rev Clin Oncol       Date:  2011-04-19       Impact factor: 66.675

3.  Time-varying pattern of recurrence risk for gastric cancer patients.

Authors:  Xing-Yu Feng; Ying-Bo Chen; Wei Wang; Yuan-Xiang Guan; Yuan-Fang Li; Shi Chen; Xiao-Wei Sun; Wei Li; Da-Zhi Xu; You-Qing Zhan; Xiao-Shi Zhang; Zhi-Wei Zhou
Journal:  Med Oncol       Date:  2013-02-24       Impact factor: 3.064

4.  Time to breast cancer relapse predicted by primary tumour characteristics, not lymph node involvement.

Authors:  Danielle J Fitzpatrick; Christine S Lai; Robert F Parkyn; David Walters; Vladimir Humeniuk; David C A Walsh
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

5.  Mathematical Modeling of Tumor-Tumor Distant Interactions Supports a Systemic Control of Tumor Growth.

Authors:  Sebastien Benzekry; Clare Lamont; Dominique Barbolosi; Lynn Hlatky; Philip Hahnfeldt
Journal:  Cancer Res       Date:  2017-07-20       Impact factor: 12.701

Review 6.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Tumor dormancy due to failure of angiogenesis: role of the microenvironment.

Authors:  George N Naumov; Judah Folkman; Oddbjorn Straume
Journal:  Clin Exp Metastasis       Date:  2008-06-18       Impact factor: 5.150

Review 8.  Metastasis dormancy in estrogen receptor-positive breast cancer.

Authors:  Xiang H-F Zhang; Mario Giuliano; Meghana V Trivedi; Rachel Schiff; C Kent Osborne
Journal:  Clin Cancer Res       Date:  2013-12-01       Impact factor: 12.531

9.  SOD derivatives prevent metastatic tumor growth aggravated by tumor removal.

Authors:  Kenji Hyoudou; Makiya Nishikawa; Yuki Kobayashi; Mai Ikemura; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Clin Exp Metastasis       Date:  2008-03-21       Impact factor: 5.150

10.  Phosphoprotein enriched in astrocytes 15 kDa (PEA-15) reprograms growth factor signaling by inhibiting threonine phosphorylation of fibroblast receptor substrate 2alpha.

Authors:  Jacob R Haling; Fen Wang; Mark H Ginsberg
Journal:  Mol Biol Cell       Date:  2009-12-23       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.